Today: 20 May 2026
Browse Category

NASDAQ:ALNY 20 December 2025 - 13 January 2026

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Alnylam shares fell 0.1% to $370.39 Tuesday afternoon after the company projected 2026 net product revenue between $4.9 billion and $5.3 billion. Preliminary 2025 sales were disclosed at $2.987 billion. Analysts remained mostly positive but flagged possible weakness for Amvuttra next quarter. The update came as Alnylam outlined its new five-year strategy at the J.P. Morgan Healthcare Conference.
13 January 2026
··
Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam shares fell 6.7% to $370.91 after preliminary fourth-quarter sales for Amvuttra missed Wall Street estimates. The company reported about $827 million in Amvuttra revenue, below analyst expectations of $852 million. Alnylam set 2026 product revenue guidance at $4.9 billion to $5.3 billion and outlined a new five-year plan. Full results are due in February.
13 January 2026
···
Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam shares fell 6.7% to $370.91 in after-hours trading Monday after the company issued 2026 sales guidance and launched its “Alnylam 2030” plan. Preliminary Q4 sales of Amvuttra reached about $827 million, missing some estimates. Management projected 2026 net product revenue of $4.9–$5.3 billion, mostly from its TTR franchise. The company targets over 25% annual revenue growth through 2030.
12 January 2026
···
Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Alnylam Pharmaceuticals closed up 1.87% at $407.73 Monday, its first session as a Nasdaq-100 constituent. The stock slipped 0.12% after hours. Index inclusion drove trading volume to about 1.05 million shares. Alnylam recently announced a $250 million expansion of its Massachusetts manufacturing site.
23 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Alnylam Pharmaceuticals joined the Nasdaq-100 Index on Dec. 22, 2025, as the annual reconstitution took effect before the market opened. Shares traded near $405.60, up 1.3% from the prior close. The company recently announced a $250 million U.S. manufacturing expansion and reported strong adoption of its AMVUTTRA therapy for transthyretin amyloidosis.
22 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Alnylam Pharmaceuticals joins the Nasdaq-100 before the U.S. market opens Dec. 22, prompting index-tracking funds to adjust positions. Shares last closed at $400.23. The company’s drug Amvuttra recently secured routine NHS use in England and Health Canada approval for ATTR cardiomyopathy. Alnylam also announced a $250 million manufacturing expansion and new FDA recognition for its technology platform.
22 December 2025
···
Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals (ALNY) closed Friday, Dec. 19, 2025, at $400.23, up 1.15% on heavy volume of 12.6 million shares, with little movement after hours. The Nasdaq-100 reconstitution takes effect before the U.S. market opens Monday, Dec. 22, adding Alnylam to the index. Friday’s session saw record derivatives expirations, amplifying trading volume.
20 December 2025
·

Stock Market Today

  • Stocks Added to Zacks Strong Sell List on May 20th: BRCC, CVE, MITT
    May 20, 2026, 5:27 AM EDT. Three stocks joined the Zacks Rank #5 (Strong Sell) list on May 20th. BRC Inc. (BRCC), a coffee and apparel seller, saw its current year earnings estimate cut by 33.3%. Cenovus Energy Inc. (CVE), an oil and gas producer, had its earnings forecast lowered by 24.5%. AG Mortgage Investment Trust (MITT), a residential mortgage REIT, faced a 17.5% earnings revision downward. These revisions reflect growing bearish sentiment as analysts adjust expectations. The Zacks Rank #5 indicates a strong sell recommendation based on recent downward earnings revisions over 60 days.

Latest articles

Wall Street Puts $150 Target on Intel in AI Push

Wall Street Puts $150 Target on Intel in AI Push

20 May 2026
Intel shares rose 2.43% to $110.80 on Tuesday, ending a five-day losing streak. The stock rebounded as analysts raised price targets, citing demand for AI server CPUs. Intel traded between $102.40 and $113.07 during the session. The Nasdaq Composite fell 0.84%, with Nvidia and AMD also down.
Marvell shares active as earnings approach, AI chip focus in view

Marvell shares active as earnings approach, AI chip focus in view

20 May 2026
Marvell Technology shares rose 4.53% to $184.25 in premarket trading Wednesday, extending Tuesday’s 4.35% gain. The company will report fiscal Q1 2027 results after the close on May 27. Analysts at Evercore ISI, Melius Research, and CLSA raised price targets, citing strong demand for custom AI chips. Marvell posted record fiscal 2026 revenue of $8.195 billion in March.
SpaceX restarts Starlink launches after satellite mishap — and another Falcon 9 is already queued

SpaceX IPO Moves Closer as Goldman Nears Top Role in $1.75 Trillion Listing

20 May 2026
Goldman Sachs is set to lead SpaceX’s planned IPO, which could become the largest in history, with a targeted valuation of about $1.75 trillion, Reuters reported. SpaceX aims to publish its prospectus as soon as Wednesday and list on Nasdaq under the ticker SPCX as early as June 12. The company’s next Starship test flight is scheduled for May 21 from Texas. Morgan Stanley, Bank of America, Citigroup, and JPMorgan are also expected to play major roles.
Go toTop